RegMedNet

What happened in March? Get quick insights in Dusko Ilic's monthly industry updates, including an in vivo CRISPR gene-editing therapy for hereditary angioedema: hubs.ly/Q04gM8hT0

Catch up on the latest news in cell and gene therapy >>> hubs.ly/Q04gDgJz0 This week: 👉 The UK’s MHRA has launched a nationwide consultation to modernize gene therapy regulation 👉 OrganaBio LLC has acquired Excellos Inc.’s operating assets 👉 Fractyl Health, Inc. has received Clinical Trial Application authorization in the Netherlands to initiate a Phase I/II study of a gene therapy for type 2 diabetes

Laying the foundations for a robust stem cell workflow "It is a widespread misconception that post-thaw viability is the most suitable parameter to assess the quality and performance of cryopreservation media” says Hagen Wieland, Team leader of Research and Development at PromoCell. Read the full interview for more >>> hubs.ly/Q04fXqYX0

Researchers from Utah State University have demonstrated the potential of CRISPR-Cas12a2 to selectively eliminate target cells while minimizing off-target effects >>> hubs.ly/Q04gplMT0

Improved cytokine recovery means better CAR-T potency data. In this Application Note, @ThermoFisher details how an automated workflow improves recovery of key cytokines (e.g., IFN-γ, GM-CSF, TNF-α). See the complete data >>>hubs.ly/Q04ghdLQ0

This Application Note demonstrates how @ThermoFisher’s automated workflow improves recovery of key cytokines, maintains high linearity across 18 cytokine targets and standardizes procedures, reducing variability. Explore the methodology and improve your CAR-T development >>> hubs.ly/Q04ghpCd0

In this interview, PromoCell experts Lucía Cespón (GMP Business Unit Lead) and Maximilian Gert-Kleint (Material Compliance Manager) delve into the key considerations for raw materials and supply chain management in cell and gene therapy development. Discover their insights here >>> hubs.ly/Q04gd9mN0

Delve into the end-to-end stem cell therapy development process; this infographic highlights the steps needed to ensure consistency and functionality. Download the infographic now >>> hubs.ly/Q04fXscn0

AAVs are the most common vectors used in FDA-approved gene therapies thanks to their safety profile, ability to target specific tissues and long-term gene expression. Check out this article to explore the biology of AAV vectors, their applications in gene therapy, challenges and future directions >>> hubs.ly/Q04f5tlL0

From ensuring product safety to meeting regulatory expectations, this Spotlight feature dives deep into raw materials and supply chain management for regenerative medicines. This feature includes expert insights, journal content and more >>> hubs.ly/Q049Sky-0

There's still time to visit us at booth 2101! Sign up today and receive a free eBook featuring peer-reviewed journal articles. Don't miss out! #ISCT2026

Catch up on the latest news in cell and gene therapy >>> hubs.ly/Q04fNKhf0 This week: 👉 FUJIFILM Biosciences and NextCell Pharma AB entered into a strategic collaboration to overcome challenges in mesenchymal stromal cell research with the commercial launch of NextCell-Cord RUO 👉 INmune Bio Inc. and Anthony Nolan expanded their multitarget MSC platform 👉 Bracco Imaging provided an opportunity to rethink selection through the launch of the BubbleGen™ platform 👉 Latus Bio secured US$97 million in Series A financing

Another day at ISCT, another chance to WIN! 🎉 Haven't stopped by booth 2101 yet? You're missing out on your chance to enter our prize draw and win a custom LEGO set!

Among the most critical yet often underappreciated aspects of cell and gene therapy manufacturing is the qualification of raw materials. Understanding what makes materials suitable for therapeutic use is essential for successful manufacturing. In this feature, explore the essentials of raw material qualification, including the regulatory frameworks that govern their use and the key factors that must be considered − such as supply chain continuity and vendor qualification processes >>> hubs.ly/Q04fH3490 Don't forget to check out our Spotlight on raw materials and supply chain: hubs.ly/Q04fGWnh0

On our tour of the exhibition floor at #ISCT2026 we couldn’t resist stopping by to see the team at PromoCell who are sponsoring our Spotlight feature on the topic of raw materials and supply chain! If you have a couple of minutes to spare between sessions, why not fill in our quick Spotlight survey for a chance to win a US$50 voucher or have a donation made to a charity of your choice? Share your insights here >>> hubs.ly/Q04fCg2T0 Or explore the full feature for content about: • The importance of sourcing and qualifying high-quality raw materials • The benefits of xeno-free and animal component-free media • How proactive risk management approaches can strengthen supply chain resilience Check it out: hubs.ly/Q04fClPd0

#ISCT2026 has kicked off! Stop booth #2101 (upstairs) to chat about our upcoming projects, plus enter into the prize draw to win one of our custom LEGO sets!

Struggling with GMP compliance for your cell therapy applications? Find out how PromoCell's Custom GMP Services and off-the-shelf PromoExQ media can help streamline your path to clinical applications >>> hubs.ly/Q049SlBD0

Why does raw material qualification matter? The complexity of manufacturing cell and gene therapies presents unique challenges that extend far beyond traditional pharmaceutical production. Among the most critical yet often underappreciated aspects of this manufacturing process is the qualification of raw materials. Understanding what raw materials are, why their qualification matters, is essential for any organization developing cell and gene therapies. Read a breakdown of what makes this process important >>> bit.ly/4w42ssy

Top stem cell-based therapies taking the field by storm >>> bit.ly/42Ipvvq In this feature, we explored some of the most promising applications of stem cell-based therapies, including therapies being developed by Osaka Metropolitan University, CellProthera, Massachusetts Eye and Ear, BlueRock Therapeutics, Oryon Cell Therapies and NextCell Pharma.

We want to hear from you! We’re shining a #spotlight on raw materials and supply chain management for cell and gene therapies. Take the survey and share your experience >>> hubs.ly/Q049Srdk0